Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sensus Healthcare, Inc. is a medical device company focused on the development, manufacture, and commercialization of non-invasive radiation therapy systems for the treatment of skin cancers and keloids. The company operates within the medical devices and oncology treatment industries, specifically targeting dermatology, radiation oncology, and surgical practices. Its primary revenue is generated from the sale of proprietary superficial radiation therapy systems, recurring service contracts, and consumables associated with its installed base.
The company’s core product portfolio centers on the SRT Systems platform, which is positioned as a clinically proven, non-surgical alternative to Mohs surgery for certain non-melanoma skin cancers and for post-surgical keloid treatment. Founded in 2010, Sensus Healthcare evolved from a technology-driven startup into a publicly traded company, completing its initial public offering in 2016. Since then, it has expanded its commercial footprint and invested in next-generation radiation delivery technologies to strengthen its niche positioning in dermatologic oncology.
Business Operations
Sensus Healthcare operates primarily through a single reportable business segment focused on the design, manufacturing, and sale of SRT Systems and related services. Revenue is derived from capital equipment sales, service and maintenance agreements, software upgrades, and consumable accessories. The company controls proprietary software and treatment protocols embedded within its systems, which are designed to enhance treatment precision and workflow efficiency for clinical providers.
Operations are conducted through a vertically integrated model that includes in-house product development, regulatory compliance, and direct sales. While the majority of sales are generated in the United States, the company also supports international customers through distributors and strategic partners. Sensus Healthcare does not report material joint ventures but maintains distributor relationships to facilitate market access outside its domestic footprint.
Strategic Position & Investments
The company’s strategic direction emphasizes expanding adoption of superficial radiation therapy as a standard-of-care alternative for appropriate dermatologic indications. Growth initiatives include increasing penetration in dermatology and radiation oncology practices, expanding clinical evidence supporting its technology, and enhancing recurring revenue through service contracts and system upgrades. Sensus Healthcare has also focused on broadening indications for use, including keloid treatment, to diversify its clinical applications.
Investment activity has been primarily organic, centered on research and development of next-generation SRT platforms and software-driven treatment optimization. The company has not disclosed large-scale transformative acquisitions, and available public filings do not indicate ownership of significant portfolio companies. Its strategic positioning is built on regulatory clearance, clinical data, and a focused product portfolio rather than broad diversification across medical device categories.
Geographic Footprint
Sensus Healthcare is headquartered in Florida, United States, which serves as its primary operational and administrative center. The company’s core market is North America, where it maintains the highest concentration of installed systems and customer relationships across dermatology and oncology practices.
Internationally, Sensus Healthcare has established a presence in parts of Europe, Asia-Pacific, and Latin America through third-party distributors. While international revenue represents a smaller portion of total sales compared to the U.S. market, management has identified global expansion as a longer-term growth opportunity, particularly in regions with rising skin cancer incidence and limited access to surgical dermatology services.
Leadership & Governance
Sensus Healthcare is led by an executive team with experience in medical devices, healthcare operations, and public company management. The leadership philosophy emphasizes disciplined growth, regulatory compliance, and clinical validation as foundations for long-term value creation.
Key executives include:
- Joseph C. Sardano – Chairman of the Board and Chief Executive Officer
- Michael D. Sardano – Vice Chairman and President
- Ismael Guerrero – Chief Financial Officer
- Richard Bryne – Chief Operating Officer
The board of directors provides oversight of strategy, risk management, and corporate governance, with a focus on aligning product development and commercialization efforts with shareholder interests and clinical outcomes.